Following the publication of the original article [1], the authors reported that they had supplied the incorrect figure 6 for publication. The correct Fig. 6 is given in this correction article. The results and conclusions described therein are not affected by these corrections. The authors sincerely apologize for the error. This has now been included in this correction article.
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.